In this framework, the programmed cell death protein-1 (PD-1) and its ligands, PD-L1 and PD-L2, are among the most well-validated and effective immunotherapeutic targets in cancer, autoimmune disorders, and infectious diseases [1,2]. The gene discussed is PDCD1; the disease is cancer.